LMTK3-IN-1是一种 ATP 竞争性 LMTK3 抑制剂，能通过泛素蛋白酶体途径降解 LMTK3，在乳腺癌细胞系中展现出抗癌活性，适用于癌症研究。

BAY 474 is a tyrosine-protein kinase c-Met inhibitor and a structural genomics consortium (SGC) epigenetics probe.

c-Met-IN-15是一种c-Met激酶抑制剂。

SU 5616是一种有机化合物，可能通过调控酪氨酸激酶信号转导来影响细胞增殖。它在癌症和细胞生物学研究中具有潜力。

Zongertinib是一种有效的 HER2 和 EGFR 酪氨酸激酶抑制剂，IC₅₀ 分别为 13 nM 和 579 nM。该化合物展现出显著的抗肿瘤活性，特别适用于多种实体瘤的研究，具有潜在的癌症治疗应用。

C-Met inhibitor D9是一种选择性的c-Met抑制剂，用于调节细胞增殖和迁移，主要用于研究癌症和其他疾病的治疗。

Risvodetinib是一种高效的蛋白酪氨酸激酶抑制剂，主要通过抑制 Abelson 家族激酶（如 c-Abl1、c-Abl2 和 c-kit）的活性，具有用于白血病等癌症研究的潜力。

Elzovantinib是一种 SRC、MET 和 c-FMS 的抑制剂，具有抗癌和治疗各种癌症的潜力。

c-Met/RON Dual Kinase Inhibitor is a potent inhibitor against the kinase activities of HGF receptor c-Met and MSP (Macrophage Stimulating Protein) receptor RON with IC50 of 4 and 9 nM, respectively, and it is reported to inhibit NIH3T3 TRP-Met and U-87 tumor growth in mice in vivo in a dose-dependent manner.

JNJ-38877605 is an ATP-competitive inhibitor of c-Met with IC50 of 4 nM.

MK8033 HCl is a specific dual ATP competitive c-Met/Ron inhibitor (IC50=1 nM Wt c-Met) under investigation as a treatment for cancer.

SGX-523 is a potent and selective c-Met inhibitor with IC50 of 4 nM.

AMG-337 is a potent, highly selective and ATP-competitive MET kinase inhibitor with an IC50 of < 5nM in enzymatic assays.

Bozitinib (PLB-1001) is a highly selective c-MET kinase inhibitor with blood-brain barrier permeability. Bozitinib (PLB-1001) is a ATP-competitive small-molecule inhibitor, binds to the conventional ATP-binding pocket of the tyrosine kinase superfamily[1].

SAR125844 is a potent and highly selective c-Met inhibitor with potential antineoplastic activity.

INCB28060 is a potent and selective c-MET kinase inhibitor. INCB28060 inhibits c-MET kinase activity with an average IC50 of 0.13 nM.

c-Met Inhibitor 1 is a c-Met receptor signaling pathway inhibitor, used for the treatment of cancer including gastric, glioblastoma, and pancreatic cancer.

PF-04217903 is a selective ATP-competitive c-Met inhibitor with IC50 of 4.8 nM, susceptible to oncogenic mutations (no activity to Y1230C mutant).

Savolitinib is an orally bioavailable inhibitor of the c-Met receptor tyrosine kinase (IC50= 5 nM) with potential antineoplastic activity.

EMD 1214063 is a potent and selective c-Met inhibitor with IC50 of 4 nM, > 200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer.